Evoke Pharma (EVOK) Receives $3M in Proceeds from Existing Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
October 1, 2024 8:30 AM EDTNantahala to nominate 2 board seats
Portion of the proceeds received from warrants executed at $8.16/share
SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants.
The approximately $3.0 million in gross proceeds will be used to support working capital and general corporate purposes,... More
